Electrophysiological and antiarrhythmic actions of the κ agonist PD 129290, and its R,R (+)‐enantiomer, PD 129289
Open Access
- 1 December 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (4) , 1579-1585
- https://doi.org/10.1111/j.1476-5381.1993.tb14004.x
Abstract
1 The S,S (−)-enantiomer PD 129290, a κ agonist, and its corresponding inactive R,R (+)-enantiomer (PD 129289) were studied in rat isolated hearts and in intact rats for cardiovascular and antiarrhythmic actions. The electrophysiological actions of PD 129290 were also studied in rat isolated cardiac myocytes using voltage clamp. 2 Ventricular pressure, heart rate and ECG were studied in isolated hearts while blood pressure, heart rate and ECG were studied in pentobarbitone-anaesthetized rats. In the latter, responses to electrical stimulation and coronary occlusion were also investigated. 3 In isolated hearts both enantiomers, over the concentration range 2–16 μm, dose-dependently reduced systolic ventricular pressure and heart rate while prolonging the P–R and QRS intervals of the ECG. 4 At doses of 1–32 μmol kg−1 both enantiomers reduced blood pressure and heart rate in anaesthetized rats. In addition, both enantiomers increased the size of the RSh and increased P–R, QRS, and Q–T intervals of the ECG. The thresholds for premature beats and ventricular fibrillation were dose-dependently increased by PD 129289. At lower doses PD 129290 decreased thresholds. These decreases were blocked by naloxone to reveal underlying increases similar to those seen with PD 129289. Both enantiomers increased refractory periods. 5 Naloxone (8 μmol kg−1) did not alter any of the actions of PD 129290, except to abolish the initial decreases in thresholds in intact rats seen with lower doses of PD 129290. 6 Both enantiomers (2 and 8 μmol kg−1) equally reduced arrhythmias in anaesthetized rats subject to occlusion of a coronary artery. 7 In rat isolated cardiac myocytes 20 μm PD 129290, in the presence and absence of naloxone decreased the amplitude of the transient sodium current by about 50% without affecting the voltage-dependence of activation or inactivation of this current. 8 The antiarrhythmic actions of both enantiomers appear to primarily result from their Class I (sodium channel blockade) properties which are independent of κ agonism.Keywords
This publication has 18 references indexed in Scilit:
- A new ECG measure (RSh) for detecting possible sodium channel blockade in vivo in ratsJournal of Pharmacological and Toxicological Methods, 1992
- Cardiovascular actions of the κ‐agonist, U‐50,488H, in the absence and presence of opioid receptor blockadeBritish Journal of Pharmacology, 1992
- Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusionEuropean Journal of Pharmacology, 1992
- Highly selective .kappa.-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted cyclohexyl]arylacetamide derivativesJournal of Medicinal Chemistry, 1990
- Mechanisms underlying the antiarrhythmic properties of β‐adrenoceptor blockade against ischaemia‐induced arrhythmias in acutely prepared ratsBritish Journal of Pharmacology, 1989
- Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemiaCardiovascular Research, 1988
- The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusionCardiovascular Research, 1988
- An improved perfusion apparatus for small animal heartsJournal of Pharmacological Methods, 1986
- Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmicsCanadian Journal of Physiology and Pharmacology, 1983
- The actions of prostaglandins I2 and E2 on arrhythmias produced by coronary occlusion in the rat and dogProstaglandins, 1979